https://www.youtube.com/watch?v=6VxMT1-kMjQ
Ola Landgren, MD, PhD, of the Sylvester Comprehensive Cancer Center, joins Blood Cancers Today to discuss quadruplet therapy in newly diagnosed multiple myel

https://medicalxpress.com/news/2024-05-qa-quadruple-therapies-future-multiple.html
Credit: Wikipedia/CC BY-SA 3.0. The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated

https://bloodcancerstoday.com/post/how-quadruplet-therapy-is-changing-the-myeloma-treatment-landscape
Dr. Landgren further discussed how quadruplet therapy is changing the MM treatment landscape, especially by deepening responses and prolonging progression-free and overall survival. "With modern, immunotherapy-based, effective therapies, we can deliver good outcomes to all patients independent of age or performance status," he said.

https://oncodaily.com/insight/88922.html
C. Ola Landgren, Chief of the Division of Myeloma at University of Miami and Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center, shared a post on X: " How Quadruplet Therapy Is Changing the Myeloma Treatment Landscape. Summary of Latest News From ASCO24 Focusing on Newly Diagnosed Myeloma Therapy.. Watch here."

https://www.onclive.com/view/quadruplet-therapy-and-early-line-car-t-cell-therapy-approvals-mark-shifting-standards-in-multiple-myeloma
Carvykti is the first and only BCMA-targeted treatment approved by the US FDA for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. News

https://www.ajmc.com/view/ash-2023-multiple-myeloma-s-shifting-landscape-trials-and-clinical-perspectives
The Future of Multiple Myeloma Treatment. EP: 9. ASH 2023: Multiple Myeloma's Shifting Landscape: Trials and Clinical Perspectives. EP: 10. Multiple Myeloma Frontline Horizon: Quads, Bispecifics

https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(21)01248-9/pdf
Transplant-eligible multiple myeloma patients are generally treated with a triplet regimen, often with lenalidomide, bortezomib, and dexamethasone (RVD), as a standard of care.1 After autologous stem cell transplantation (ASCT), lenalidomide is an established maintenance therapy, given the Phase 3 trials showing increased progression free

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11035596/
Introduction. Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor [1-4] and immunomodulatory [5-7] mechanism of action, demonstrating greater cytotoxicity toward multiple myeloma (MM) cells ex vivo compared with analogs of other CD38 antibodies [].Daratumumab is approved as a monotherapy and in combination with standard-of-care regimens for patients with

https://www.uchicagomedicine.org/forefront/cancer-articles/2022/september/quadruplet-treatment-delays-the-need-for-stem-cell-transplantation-in-newly-diagnosed-multiple-myeloma-patients
A clinical trial at the University of Chicago Medicine Comprehensive Cancer Care Center is showing promise in treating newly diagnosed multiple myeloma patients with a four-drug (quadruplet) therapy. Multiple myeloma (MM) is a rare cancer of plasma cells, a type of white blood cell in the bone marrow that produces antibodies. Treating MM

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334731/
Abstract. Multiple myeloma is one of the most common hematological malignancies, affecting mainly elderly patients. The treatment landscape for the management of this disease has evolved significantly over the past 15 years, and a vast array of therapeutics is now available, including immunomodulatory drugs, proteasome inhibitors, histone

https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2022/11/23/triplet-vs.-quadruplet-therapy-in-multiple-myeloma-choosing-the-right-treatment
Multiple myeloma refers to blood cancer found within the plasma cells of bone marrow. It is rarely curable, but treatment can be used to slow down disease progression and support a better quality of life. In the treatment of multiple myeloma, triplet therapy is the current standard of care for most patients, and National Comprehensive Cancer Network Guidelines ® identify standard treatment

https://www.cancernetwork.com/view/novel-quadruplet-therapy-shows-promise-multiple-myeloma
Dr. Pawlyn: Patients receiving the novel quadruplet therapy were all in the transplant-eligible pathway of the trial. They were randomized to receive the quadruplet, which combines the novel proteasome inhibitor carfilzomib, along with the second-generation immunomodulatory agent lenalidomide, cyclophosphamide, and dexamethasone (KCRD), or they

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00097-8/abstract
In the past 15 years, treatment frameworks for newly diagnosed multiple myeloma have radically changed. It is important to recall that as recently as 2010, Rajkumar and colleagues1 presented ECOG E4A03, which was a phase 3 trial examining the role of lenalidomide, combined with two different dosing regimens for dexamethasone, that showed a 68% overall response rate (ORR; 10% complete remission

https://www.cancernetwork.com/view/expert-perspectives-on-quadruplet-therapy-regimens-for-patients-with-multiple-myeloma
The panel shares some personal experiences with treating patients with multiple myeloma with a quadruplet therapy regimen. ... Looking Ahead in the Multiple Myeloma Treatment Landscape. EP: 13. ... and how these findings may change the treatment paradigm.

https://medicalxpress.com/news/2024-05-qa-quadruple-therapies-future-multiple.pdf
The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients ... How might quadruple therapy change treatment in

https://www.nature.com/articles/s41408-023-00804-y
With the treatment landscape rapidly changing in response to emerging clinical trial data and approvals of several new drugs and additional combinations, it is critically important to focus on

https://www.cancernetwork.com/view/determining-who-should-get-quadruplet-vs-triplet-therapy-in-multiple-myeloma
Experts from Emory University School of Medicine who specialize in multiple myeloma gathered to discuss the current treatment landscape, including which patients are best suited to a quadruplet or triplet regimen. ... appropriate use of a triplet vs quadruplet therapy, and how they would approach selecting patients for each resoective regimen

https://www.targetedonc.com/view/multiple-myeloma-awareness-month-quadruplet-regimens-create-new-outlook-for-sequencing-therapy
Application error: a client-side exception has occurred (see the browser console for more information). The evolving landscape for treating multiple myeloma has seen significant improvement for patients, giving them better options. One of the key regimens added to this landscape is the use of a new quadruplet regimen.

https://www.onclive.com/view/multiple-myeloma-landscape-grows-at-rapid-pace-with-quadruplets-and-bcma-directed-therapy
Douglas W. Sborov, MD, MS, discusses key data and therapeutic developments that have reshaped the treatment of patients with newly diagnosed and relapsed/refractory multiple myeloma.

https://www.cancernetwork.com/view/the-current-treatment-landscape-for-relapsed-refractory-multiple-myeloma
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm. Prolonged PFS Observed in Isatuximab Combo in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

https://www.onclive.com/view/dara-krd-quadruplet-makes-waves-in-newly-diagnosed-multiple-myeloma
Costa LJ, Chhabra S, Medvedova E, et al. Quadruplet induction therapy, ASCT and MRD-modulated consolidation and treatment cessation in newly diagnosed multiple myeloma: final analysis of the

https://www.cancernetwork.com/view/recap-a-review-of-the-treatment-landscape-in-multiple-myeloma
At an Around the Practice ® program hosted by CancerNetwork®, experts spoke about the rapidly evolving landscape of treatments in multiple myeloma. The discussion was led by Rafael Fonseca, MD, who is the director for Innovation and Transformational Relationships, and Mayo Clinic Distinguished Investigator at the Mayo Clinic campus in Phoenix, Arizona.

https://www.pharmacytimes.com/view/from-research-to-practice-new-treatment-modalities-for-patients-with-multiple-myeloma
Ryan Haumschild discusses the evolving treatment landscape for patients with multiple myeloma. Ryan Haumschild, PharmD, MS, MBA, CPEL, vice president of ambulatory pharmacy at Emory Healthcare Winship Cancer Institute, provided valuable insights into the evolving treatment modalities in multiple myeloma (MM) at the Oncology Pharmacists Connect

https://www.cancernetwork.com/view/quadruplet-regimens-for-transplant-eligible-multiple-myeloma
Saad Z. Usmani, MD: That's an excellent summary of the KRd [carfilzomib, lenalidomide, dexamethasone] data and where things are headed. Transcript edited for clarity. Implications of updated data from the GRIFFIN trial, in terms of using quadruplet therapy to manage patients with newly diagnosed multiple myeloma who are eligible for transplant.

https://www.cancernetwork.com/view/the-evolving-treatment-landscape-of-transplant-eligible-newly-diagnosed-multiple-myeloma
The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.